Risk factors for developing ventilator-associated lower respiratory tract infection in patients with severe COVID-19: a multinational, multicentre study, prospective, observational study
- PMID: 37085552
- PMCID: PMC10119842
- DOI: 10.1038/s41598-023-32265-5
Risk factors for developing ventilator-associated lower respiratory tract infection in patients with severe COVID-19: a multinational, multicentre study, prospective, observational study
Abstract
Around one-third of patients diagnosed with COVID-19 develop a severe illness that requires admission to the Intensive Care Unit (ICU). In clinical practice, clinicians have learned that patients admitted to the ICU due to severe COVID-19 frequently develop ventilator-associated lower respiratory tract infections (VA-LRTI). This study aims to describe the clinical characteristics, the factors associated with VA-LRTI, and its impact on clinical outcomes in patients with severe COVID-19. This was a multicentre, observational cohort study conducted in ten countries in Latin America and Europe. We included patients with confirmed rtPCR for SARS-CoV-2 requiring ICU admission and endotracheal intubation. Only patients with a microbiological and clinical diagnosis of VA-LRTI were included. Multivariate Logistic regression analyses and Random Forest were conducted to determine the risk factors for VA-LRTI and its clinical impact in patients with severe COVID-19. In our study cohort of 3287 patients, VA-LRTI was diagnosed in 28.8% [948/3287]. The cumulative incidence of ventilator-associated pneumonia (VAP) was 18.6% [610/3287], followed by ventilator-associated tracheobronchitis (VAT) 10.3% [338/3287]. A total of 1252 bacteria species were isolated. The most frequently isolated pathogens were Pseudomonas aeruginosa (21.2% [266/1252]), followed by Klebsiella pneumoniae (19.1% [239/1252]) and Staphylococcus aureus (15.5% [194/1,252]). The factors independently associated with the development of VA-LRTI were prolonged stay under invasive mechanical ventilation, AKI during ICU stay, and the number of comorbidities. Regarding the clinical impact of VA-LRTI, patients with VAP had an increased risk of hospital mortality (OR [95% CI] of 1.81 [1.40-2.34]), while VAT was not associated with increased hospital mortality (OR [95% CI] of 1.34 [0.98-1.83]). VA-LRTI, often with difficult-to-treat bacteria, is frequent in patients admitted to the ICU due to severe COVID-19 and is associated with worse clinical outcomes, including higher mortality. Identifying risk factors for VA-LRTI might allow the early patient diagnosis to improve clinical outcomes.Trial registration: This is a prospective observational study; therefore, no health care interventions were applied to participants, and trial registration is not applicable.
© 2023. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Figures




Similar articles
-
Risk factors for ventilator-associated lower respiratory tract infection in COVID-19, a retrospective multicenter cohort study in Sweden.Acta Anaesthesiol Scand. 2024 Feb;68(2):226-235. doi: 10.1111/aas.14338. Epub 2023 Sep 26. Acta Anaesthesiol Scand. 2024. PMID: 37751991
-
Early bacterial co-infections and ventilator-associated lower respiratory tract infections among intubated patients during the first and second COVID-19 waves: a European comparative cohort study.Respir Res. 2025 Mar 5;26(1):83. doi: 10.1186/s12931-025-03148-2. Respir Res. 2025. PMID: 40045262 Free PMC article.
-
Relationship between SARS-CoV-2 infection and the incidence of ventilator-associated lower respiratory tract infections: a European multicenter cohort study.Intensive Care Med. 2021 Feb;47(2):188-198. doi: 10.1007/s00134-020-06323-9. Epub 2021 Jan 3. Intensive Care Med. 2021. PMID: 33388794 Free PMC article.
-
Should We Treat Ventilator-Associated Tracheobronchitis with Antibiotics?Semin Respir Crit Care Med. 2017 Jun;38(3):264-270. doi: 10.1055/s-0037-1602582. Epub 2017 Jun 4. Semin Respir Crit Care Med. 2017. PMID: 28578551 Review.
-
Inhaled antibiotic therapy for ventilator-associated tracheobronchitis and ventilator-associated pneumonia: an update.Adv Ther. 2011 Sep;28(9):728-47. doi: 10.1007/s12325-011-0051-z. Epub 2011 Aug 8. Adv Ther. 2011. PMID: 21833701 Review.
Cited by
-
Incidence, microbiological and immunological characteristics of ventilator-associated pneumonia assessed by bronchoalveolar lavage and endotracheal aspirate in a prospective cohort of COVID-19 patients: CoV-AP study.Crit Care. 2023 Sep 26;27(1):369. doi: 10.1186/s13054-023-04658-5. Crit Care. 2023. PMID: 37749631 Free PMC article.
-
Tracheal tube infections in critical care: A narrative review of influencing factors, microbial agents, and mitigation strategies in intensive care unit settings.SAGE Open Med. 2024 Dec 16;12:20503121241306951. doi: 10.1177/20503121241306951. eCollection 2024. SAGE Open Med. 2024. PMID: 39691863 Free PMC article. Review.
-
Corticosteroids and long-term pulmonary function after critical illness due to COVID-19- a single-center cohort study.BMC Pulm Med. 2025 Apr 26;25(1):201. doi: 10.1186/s12890-025-03659-0. BMC Pulm Med. 2025. PMID: 40287680 Free PMC article.
-
Does Empirical Antibiotic Use Improve Outcomes in Ventilated Patients with Pandemic Viral Infection? A Multicentre Retrospective Study.Antibiotics (Basel). 2025 Jun 8;14(6):594. doi: 10.3390/antibiotics14060594. Antibiotics (Basel). 2025. PMID: 40558184 Free PMC article.
-
Clinical and Microbiological Impact of Implementing a Decision Support Algorithm through Microbiologic Rapid Diagnosis in Critically Ill Patients: An Epidemiological Retrospective Pre-/Post-Intervention Study.Biomedicines. 2023 Dec 16;11(12):3330. doi: 10.3390/biomedicines11123330. Biomedicines. 2023. PMID: 38137551 Free PMC article.
References
-
- Chalmers JD, Crichton ML, Goeminne PC, Cao B, Humbert M, Shteinberg M, Antoniou KM, Ulrik CS, Parks H, Wang C, et al. Management of hospitalised adults with coronavirus disease 2019 (COVID-19): A European Respiratory Society living guideline. Eur. Respir. J. 2021;57(4):1. doi: 10.1183/13993003.00048-2021. - DOI - PMC - PubMed
-
- Gundem T, Olasveengen TM, Hovda KE, Gaustad K, Schondorf C, Rostrup M, Froyshov S, Undseth O, Tonby K, Holten AR, et al. Ventilatory support for hypoxaemic intensive care patients with COVID-19. Tidsskr Nor Laegeforen. 2020;140(11):1. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous